Mast Therapeutics Inc (NYSE:MSTX) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 7,102,740 shares, an increase of 12.9% from the October 31st total of 6,290,337 shares. Approximately 3.4% of the company’s stock are sold short. Based on an average daily trading volume, of 4,295,436 shares, the days-to-cover ratio is currently 1.7 days.
Mast Therapeutics (NYSE:MSTX) traded up 0.7551% during mid-day trading on Friday, hitting $0.0934. 3,793,201 shares of the stock were exchanged. Mast Therapeutics has a 1-year low of $0.07 and a 1-year high of $0.71. The company’s market capitalization is $22.25 million. The stock has a 50 day moving average price of $0.08 and a 200 day moving average price of $0.31.
Mast Therapeutics (NYSE:MSTX) last released its earnings results on Tuesday, November 8th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, equities analysts anticipate that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.
MSTX has been the topic of a number of research reports. Zacks Investment Research raised shares of Mast Therapeutics from a “sell” rating to a “buy” rating and set a $0.25 price target on the stock in a research note on Friday, September 23rd. S&P Equity Research lifted their price target on shares of Mast Therapeutics from $0.08 to $0.09 in a research note on Friday, October 14th. Cowen and Company lowered shares of Mast Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, September 23rd. Maxim Group set a $5.00 price target on shares of Mast Therapeutics and gave the company a “buy” rating in a research note on Monday, August 8th. Finally, Roth Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Mast Therapeutics in a report on Monday, August 1st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Mast Therapeutics has an average rating of “Hold” and an average target price of $2.07.
About Mast Therapeutics